Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG0903 SMART-AC
jRCTs031180002Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and mitomycin c in anal squamous cell carcinoma (SCCA), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Incidence of dose-limiting toxicity and 3-year event-free survival proportion. Started May 2010; status: completed.
02
Drugs
tegafurmitomycin c
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on jRCTs031180002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180002.